Amyris engineers microbes to produce molecules for commercial use, beating traditional production processes based on macroorganisms or petrochemicals in cost and quality. The production method of choice is fermentation, which has revolutionized the biopharmaceutical industry in the 1980s and as production costs are riding down exponential cost curves, fermentation is now unlocking applications in cosmetics, materials and ultimately food.

Amyris is the only company pushing synthetic biology into industrial scale and is very much misunderstood by investors due to mistakes in investor communication in the past and confusion about their business model. They have already hit a commercial inflection point and have been growing revenues organically by 50%+ pa over the past 5y. The profitability inflection point will likely be reached next year as their state of the art production facility comes online and licensing deals will hit the bottom line in larger sizes. The latter are very much misunderstood as one off asset sales when they are in fact a recurring sustainable form of tech monetization turbocharging growth.